Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung cancer. Data from the Phase 1 trial of ZW191 provide readthrough to Zymeworks’ broader ADC portfolio utilizing its novel bystander active topoisomerase-1 inhibitor payload, ZD06519. [...]










